Novo Nordisk (NVO) CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial issues.
https://seekingalpha.com/news/4449657-eli-lilly-compounders-blame-novo-ceo-ouster
Novo Nordisk (NVO) CEO resigns as Eli Lilly (LLY) dominates the weight loss drug market and compounders threaten the company's financial issues.
https://seekingalpha.com/news/4449657-eli-lilly-compounders-blame-novo-ceo-ouster
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.